A primary goal of the meeting is to provide a forum where medical scientists from academia can interact with scientists from the biopharmaceutical industry, thus forging a community of academic and industry researchers who recognize that they have much to learn from each other. Rational drug discovery for neurodegenerative diseases has begun to yield compounds and treatments that are now entering clinical settings. For human studies utilizing these compounds and treatments to be maximally informative, it is crucial that scientists from academia and industry meet regularly to exchange data and ideas.
This meeting will consist of six to seven oral sessions plus one poster session. The aim is to populate half of each oral session with speakers from academia and the other half from industry; speakers will be invited as well as selected from submitted abstracts.
- Convergent and Divergent Pathways in Neurodegeneration
- Glial Biology in Neurodegeneration
- Diverse Therapeutic Strategies
- ApoE and Lipid Metabolism
- Cell Biology of Neurodegeneration
- Protein Homeostasis